34898-30-1

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
2-[4-(Trifluoromethyl)phenyl]-1H-imidazole is used as a building block for synthesizing biologically active compounds, leveraging its unique chemical properties and structure to create novel pharmaceutical agents.
Used in Antimicrobial Applications:
In the field of antimicrobial research, 2-[4-(Trifluoromethyl)phenyl]-1H-imidazole is used as a potential antimicrobial agent, targeting various types of bacteria and contributing to the development of new antibiotics.
Used in Antifungal Applications:
2-[4-(Trifluoromethyl)phenyl]-1H-imidazole is employed as an antifungal agent, exhibiting activity against various fungal species, which is crucial for the development of new antifungal medications.
Used in Anticancer Applications:
2-[4-(Trifluoromethyl)phenyl]-1H-imidazole is used as a potential anticancer agent, with ongoing research exploring its ability to target and inhibit the growth of cancer cells, offering a new avenue for cancer treatment.
Used in Medicinal Chemistry:
In the realm of medicinal chemistry, 2-[4-(Trifluoromethyl)phenyl]-1H-imidazole is utilized for its potential to contribute to the discovery and development of new therapeutic agents, given its unique properties and structural attributes.

Upstream product

• 455-19-6 4-Trifluoromethylbenzaldehyde 
• 288-32-4 1H-imidazole 
• 455-13-0 4-Iodobenzotrifluoride 
• 208718-17-6 2-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-imidazole 
• 455-18-5 4-CF₃C₆H₄CN 

Downstream Products

• 1253697-59-4 1-(phenylsulfonyl)-2-(4-(trifluoromethyl)phenyl)-1H-imidazole 

Relevant academic research and scientific papers

Addressing hERG activity while maintaining favorable potency, selectivity and pharmacokinetic properties of PPARδ modulators

One of the most commonly used strategies to reduce hERG (human ether-a-go-go) activity in the drug candidates is introduction of a carboxylic acid group. During the optimization of PPARδ modulators, some of the compounds containing a carboxylic acid were found to inhibit the hERG channel in a patch clamp assay. By modifying the basicity of the imidazole core, potent and selective PPARδ modulators that do not inhibit hERG channel were identified. Some of the modulators have excellent pharmacokinetic profiles in mice.

PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Provided herein are compounds and compositions useful in increasing PPAR8 activity. The compounds and compositions provided herein are useful for the treatment of PPAR8 related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

COMPOUNDS FOR TREATMENT OF CANCER

The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis.

COMPOUNDS FOR TREATMENT OF CANCER

The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.

PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE

The present invention provides compounds having a structure according to Formula (I) or a salt or solvate thereof, wherein ring A, X, R1, R2, R3, R4, R5 and R6, are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.

Novel imidazole derivatives

The invention is concerned with novel imidazole derivatives of formula (I), wherein m, E, R1, R2, R3, R4, R5, R6 and R7 are as defined in the description and in the claims, as we

A simple and convenient one-pot method for the preparation of heteroaryl-2-imidazoles from nitriles

A simple, convenient and high-yielding one-pot method for the synthesis of 2-heterocycle-substituted imidazoles from the corresponding nitriles has been developed. The procedure is easily scaleable and the workup does not involve chromatography. This synthesis is also applicable to the preparation of imidazoles with electron-poor aryl substituents.

Efficient and highly regioselective direct C-2 arylation of azoles, including free (NH)-imidazole, -benzimidazole and -indole, with aryl halides

The Pd- and Cu-mediated reaction of a large variety of π-electron sufficient heteroarenes, which include free (NH)-imidazoles, -benzimidazole and -indole, with aryl iodides under ligandless and base-free conditions provides regioselectively the required 2-arylheterocycle derivatives in high yields. 2-Aryl-1-phenyl-1H-imidazoles can also be prepared by a one-pot domino HALEX and Pd- and Cu-mediated arylation reactions of 1-phenyl-1H-imidazole with activated and unactivated aryl bromides under base-free and ligandless conditions. The protocol for the synthesis of 2-arylazoles involving the use of aryl iodides has been found to be suitable for the efficient preparation of three bioactive compounds and a key intermediate in the synthesis of a heparanase inhibitor.

Palladium- and copper-mediated direct C-2 arylation of azoles - Including free (NH)-imidazole, -benzimidazole and -indole - Under base-free and ligandless conditions

The first palladium- and copper-mediated C-2 arylations of thiazole, oxazole, N-methylimidazole and N-arylimidazoles, as well as of free (NH)-imidazole, -benzimidazole and -indole, with aryl iodides under ligandless and base-free conditions are described. Complete selectivity has been achieved under these unprecedented conditions, which allow the use of substrates containing base-sensitive groups, such the NH groups of imidazole, benzimidazole or indole, without their prior protection. No N-arylation products were detected in the arylation of free (NH)-imidazole, -benzimidazole and -indole. Wiley-VCH Verlag GmbH & Co. KGaA, 2006.